Arm J P, Horton C E, Spur B W, Mencia-Huerta J M, Lee T H
Department of Allergy and Allied, Respiratory Disorders, United Medical School, Guy's Hospital, London, United Kingdom.
Am Rev Respir Dis. 1989 Jun;139(6):1395-400. doi: 10.1164/ajrccm/139.6.1395.
The effects of dietary supplementation with fish oil lipids on the airways responses to allergen and neutrophil biochemistry and function have been studied in 17 atopic asthmatic subjects. Nine subjects received 18 capsules of Max-EPA (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid) a day and eight subjects received identical capsules containing olive oil, for 10 wk in a double-blind fashion. There were no differences between prediet values and those observed after dietary supplementation with Max-EPA or placebo in the dose of allergen causing an acute asthmatic response as assessed by a 35% fall in specific airways conductance (PD35), the extinction dose of allergen on skin prick testing, the histamine PD35, or the total serum IgE concentrations. Twelve of the 17 subjects developed late asthmatic responses after allergen challenge prediet. Six of these subjects received Max-EPA, and six received placebo capsules. As compared to prediet values, the magnitude of the allergen-induced late asthmatic response was significantly attenuated from 2 to 7 h after allergen challenge following dietary supplementation with Max-EPA (p less than 0.005) but not with placebo. The attenuation of the late response was not accompanied by any significant change in the clinical severity of disease as assessed by diurnal peak expiratory flow rates, symptom scores, or bronchodilator drug usage.(ABSTRACT TRUNCATED AT 250 WORDS)
在17名特应性哮喘患者中研究了膳食补充鱼油脂质对气道对变应原的反应以及中性粒细胞生物化学和功能的影响。9名受试者每天服用18粒Max-EPA胶囊(3.2克二十碳五烯酸和2.2克二十二碳六烯酸),8名受试者以双盲方式服用含橄榄油的相同胶囊,持续10周。在用特异性气道传导率下降35%(PD35)评估引起急性哮喘反应的变应原剂量、皮肤点刺试验中变应原的消退剂量、组胺PD35或总血清IgE浓度方面,饮食前值与服用Max-EPA或安慰剂进行膳食补充后观察到的值之间没有差异。17名受试者中有12名在饮食前变应原激发后出现迟发性哮喘反应。其中6名受试者接受Max-EPA,6名接受安慰剂胶囊。与饮食前值相比,膳食补充Max-EPA后变应原诱导的迟发性哮喘反应的程度在变应原激发后2至7小时显著减轻(p小于0.005),而安慰剂则无此效果。通过日间呼气峰值流速、症状评分或支气管扩张剂药物使用评估,迟发性反应的减轻并未伴随疾病临床严重程度的任何显著变化。(摘要截断于250字)